Drugs | Are you aware of the clinical indications for the following systemic therapies in lung cancer? (n=288) | Are you currently prescribing any of the following systemic therapies in lung cancer? (n=174) | Do you feel you have a good understanding of the toxicity profile of the following systemic therapies in lung cancer? (n=244) |
Targeted therapies | |||
EGFR TKI | 280 (97.2) | 170 (97.7) | 228 (93.4) |
ALK inhibitors | 257 (89.2) | 148 (85.1) | 173 (70.9) |
ROS-1 inhibitors | 183 (63.5) | 91 (44.5) | 102 (41.8) |
Monoclonal antibodies | |||
Anti-EGFR | 196 (68.1) | 68 (45.9) | 94 (38.5) |
Anti-angiogenic | 211 (73.3) | 111 (63.8) | 143 (58.6) |
Immunotherapy | |||
PD1/PD-L1 axis | 237 (82.3) | 146 (83.9) | 177 (72.5) |
CTLA4 axis | 150 (52.1) | 49 (28.2) | 92 (37.7) |
Data is presented as n (%) based on the total number of respondents shown in the column headers and corresponds to the number of YES responses to the questions; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; ALK: anaplastic lymphoma kinase; ROS-1: ROS proto-oncogene 1; PD1: programmed cell death 1; PDL1: programmed death ligand 1; CTLA4: cytotoxic T-lymphocyte-associated protein 4.